- Home
- OTLK vs MGLD Comparison
OTLK vs MGLD Comparison
Compare OTLK & MGLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- MGLD
- Stock Information
- Founded
- OTLK 2010
- MGLD 1996
- Country
- OTLK United States
- MGLD United States
- Employees
- OTLK N/A
- MGLD N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- MGLD Finance/Investors Services
- Sector
- OTLK Health Care
- MGLD Finance
- Exchange
- OTLK Nasdaq
- MGLD Nasdaq
- Market Cap
- OTLK 42.8M
- MGLD 44.8M
- IPO Year
- OTLK 2016
- MGLD N/A
- Fundamental
- Price
- OTLK $1.69
- MGLD $1.03
- Analyst Decision
- OTLK Buy
- MGLD
- Analyst Count
- OTLK 5
- MGLD 0
- Target Price
- OTLK $5.25
- MGLD N/A
- AVG Volume (30 Days)
- OTLK 4.5M
- MGLD 10.9K
- Earning Date
- OTLK 12-26-2025
- MGLD 11-07-2025
- Dividend Yield
- OTLK N/A
- MGLD N/A
- EPS Growth
- OTLK N/A
- MGLD N/A
- EPS
- OTLK N/A
- MGLD N/A
- Revenue
- OTLK $1,505,322.00
- MGLD $29,207,000.00
- Revenue This Year
- OTLK N/A
- MGLD N/A
- Revenue Next Year
- OTLK $342.80
- MGLD N/A
- P/E Ratio
- OTLK N/A
- MGLD N/A
- Revenue Growth
- OTLK N/A
- MGLD N/A
- 52 Week Low
- OTLK $0.79
- MGLD $0.64
- 52 Week High
- OTLK $5.18
- MGLD $2.10
- Technical
- Relative Strength Index (RSI)
- OTLK 59.10
- MGLD 48.30
- Support Level
- OTLK $1.76
- MGLD $0.90
- Resistance Level
- OTLK $2.02
- MGLD $1.10
- Average True Range (ATR)
- OTLK 0.20
- MGLD 0.07
- MACD
- OTLK 0.04
- MGLD 0.00
- Stochastic Oscillator
- OTLK 59.38
- MGLD 47.62
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About MGLD The Marygold Companies Inc.
The Marygold Companies Inc is a holding company that intends to focus on financial services. It is currently directing its investments towards financial services and the emerging Fintech space.